Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
5/29/2024 | $16.00 | Buy | HSBC Securities | |
1/26/2024 | Outperform → Buy | CLSA | ||
1/25/2024 | $10.00 → $15.00 | Neutral → Overweight | JP Morgan | |
11/24/2023 | Buy | Goldman | ||
11/7/2023 | $10.50 | Overweight | Morgan Stanley | |
10/16/2023 | $11.60 | Neutral → Buy | UBS | |
5/1/2023 | $6.20 | Buy → Neutral | UBS | |
4/13/2023 | Outperform → Buy | Daiwa Securities |
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an
BEIJING, Aug. 1, 2024 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the first quarter of fiscal year 2025 ended May 31, 2024. Highlights for the First Quarter of Fiscal Year 2025 Net revenues were US$414.2 million, compared to net revenues of US$275.4 million in the same period of the prior year.Loss from operations was US$17.3 million, compared to loss from operations of US$57.8 million in the same period of the prior year.Non-GAAP income from operations, which excluded share-based compensation expenses, was US$0.9 million, compared to non-GAAP loss from operations o
BEIJING, July 3, 2024 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the first quarter of fiscal year 2025 ended May 31, 2024, before the market opens on Thursday, August 1, 2024. The Company will host a corresponding conference call and live webcast at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, August 1, 2024. Please note that you will need to pre-register for conference call participation at https://register.vevent.com/register/BI0948a7548cbb4383b037c2d80666f8ec. Upon registration, you will receive an email containing parti
BEIJING, May 31, 2024 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended February 29, 2024 (the "Annual Report") with the Securities and Exchange Commission (the "SEC") on May 31, 2024, U.S. Eastern Time. The Annual Report can be accessed and downloaded on the Company's website at https://ir.100tal.com/, as well as on the SEC's website at http://www.sec.gov. Shareholders and ADS holders of the Company may request a hard copy of the Annual Report free of charge by emailing the Company at [email protected] or by writing to the following address: F
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
BEIJING, Aug. 1, 2024 /PRNewswire/ -- TAL Education Group (NYSE:TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the first quarter of fiscal year 2025 ended May 31, 2024. Highlights for the First Quarter of Fiscal Year 2025 Net revenues were US$414.2 million, compared to net revenues of US$275.4 million in the same period of the prior year.Loss from operations was US$17.3 million, compared to loss from operations of US$57.8 million in the same period of the prior year.Non-GAAP income from operations, which excluded share-based compensation expenses, was US$0.9 million, compared to non-GAAP loss from operations o
BEIJING, July 3, 2024 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the first quarter of fiscal year 2025 ended May 31, 2024, before the market opens on Thursday, August 1, 2024. The Company will host a corresponding conference call and live webcast at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, August 1, 2024. Please note that you will need to pre-register for conference call participation at https://register.vevent.com/register/BI0948a7548cbb4383b037c2d80666f8ec. Upon registration, you will receive an email containing parti
BEIJING, April 25, 2024 /PRNewswire/ -- TAL Education Group (NYSE: TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the fourth quarter and the fiscal year ended February 29, 2024. Highlights for the Fourth Quarter of Fiscal Year 2024 Net revenues was US$429.6 million, compared to net revenues of US$269.0 million in the same period of the prior year.Loss from operations was US$11.1 million, compared to loss from operations of US$44.4 million in the same period of the prior year.Non-GAAP income from operations, which excluded share-based compensation expenses, was US$9.4 million, compared to non-GAAP loss from ope
HSBC Securities resumed coverage of TAL Education with a rating of Buy and set a new price target of $16.00
CLSA upgraded TAL Education from Outperform to Buy
JP Morgan upgraded TAL Education from Neutral to Overweight and set a new price target of $15.00 from $10.00 previously
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
6-K - TAL Education Group (0001499620) (Filer)
20-F - TAL Education Group (0001499620) (Filer)
6-K - TAL Education Group (0001499620) (Filer)
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-than-expected second-quarter financial results and raised its 2024 guidance. IQVIA reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion, according to data from Benzinga Pro. IQVIA Holdings shares jumped 7.4% to $241.07 on Monday. Here are some other big stocks recording gains in today’s session. Tellurian Inc. (NASDAQ:TELL) shares surged 64.5% to
TAL Education Group (NYSE:TAL) shares are trading higher by 7.48% to $10.85 during Monday’s session. Chinese stock prices are rising following China's reduction of key interest rates. The People's Bank of China (PBOC) lowered key interest rates, including the seven-day reverse repo rate and the one-year and five-year loan prime rates. Lower interest rates reduce borrowing costs for businesses and consumers, leading to increased spending and investment. This economic stimulus can lead to higher demand for educational services as families feel more financially secure and are more willing to invest in their children’s education. Education is often considered a relatively resilient sector